Summary of COVID-19 rhu-pGSN studies

1. DiNubile et al., Adjunctive Recombinant Human Plasma Gelsolin for Severe Coronavirus Disease 2019 Pneumonia

61 patient rhu-pGSN late treatment RCT: 3% higher mortality (p=1), 48% lower ventilation (p=0.47), and 29% higher progression (p=0.73).
RCT 61 hospitalized patients with COVID-19 pneumonia showing no significant difference in survival without major organ support with recombinant human plasma gelsolin (rhu-pGSN). This double-blind, placebo-controlled trial evaluated rhu-pGSN (12 mg/kg × 3 doses over 36 hours) versus placebo in patients with WHO severity score 4-6 and evidence of hyperinflammation.
Jul 2022, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofac357/6649582, https://c19p.org/dinubile